Recent Trial Results

Over the past year, ACRIA has conducted eight clinical trials, including a study of ibalizumab, a once or twice per month monoclonal antibody injection that could make treatment adherence much simpler.  ACRIA is the largest testing site for ibalizumab and, if successful, will have contributed to the development of a new class of HIV medication. Other recent clinical trials our researchers have conducted include:

 

  • A0112: A double-blind, randomized trial to evaluate the safety and efficacy of eight weekly doses of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in HIV-infected subjects who are 18 to 65 years of age and who are on anti-retroviral therapy.
  • 1220.47 Boehringer-Ingelheim: A phase 3, randomized, double-blind and placebo-controlled study of once daily BI201335 120mg for 24 weeks and BI201335 240mg for 12 weeks in combination with pegylated interferon-α and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection.
  • Bristol-Myers Squibb ICON: A phase 2b, randomized, controlled, partially blind trial to investigate safety, efficacy, and dose-response of BMS-663068 in treatment-experienced HIV-1 infected subjects with multidrug resistance virus, followed by an open label period on the recommended dose of BMS-663608.
  • Salix CFHD3092: A phase 3, multicenter, open label evaluation of the safety and tolerability of crofelemer in HIV-positive subjects with diarrhea.
  • Boehringer-Ingelheim 1220.19: A study of the safety and efficacy of 240mg of BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic hepatitis c (HCV) genotype 1 infection in HIV/HCV co-infected patients. This is a multinational, randomized, parallel group, open label trial.
  • Pfizer A4001095: A multicenter, randomized, double-blind, comparative trial of maraviroc with darunavir/ritonavir versus emtricitabine/tenofovir with darunivir/ritonavir for the treatment of anti-retroviral-naive HIV-infected patients with CCR-5-tropic HIV-1.
  • Tobira: A phase 2, double-dummy trial of 50 or 100mg once daily doses of TBR-652 administered with emtricitabine/tenofovir (FTC/TDF) compared to efavirenz plus FTC/TDF in HIV-1 infected ARV treatment-naive adult patients with CCR5-tropic virus.
  • TaiMed TMB-202: A phase 2b, randomized, double-blind, 48-week, multicenter, placebo-controlled, dose optimizing study of ibalizumab plus an optimized background regimen versus placebo plus an optimized background regimen in treatment-experienced patients infected with HIV-1.
  • TaiMed TMB-108: A phase 1, randomized, double-blind, placebo-controlled, sequential dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ibalizumab in HIV-negative, at-risk volunteers.

 

To learn more about drug trials please email info@acria.org